Operating through 68 Company-operated treatment centers, Greenbrook is a leading provider of TMS, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 220,000 TMS treatments to over 6,000 patients struggling with depression.
For copies of our financial statements and other continuous disclosure filings, please see the Greenbrook TMS profile at SEDAR (System for Electronic Document Analysis and Retrieval) by clicking the link below.
Greenbrook TMS Inc. will attend the Bloom Burton & Co. Healthcare Investor Conference at the Metro Toronto Conference Centre, 255 Front Street West, Toronto, Ontario. Mr. Bill Leonard, President and Chief Executive Officer will present to attendees at 10:30 a.m. on Wednesday May 1st, 2019.
Bill Leonard, President and Chief Executive Officer and Erns Loubser, Chief Financial Officer, will host a conference call at 10:00 a.m. (Eastern Time) on May 10, 2019 to discuss the financial results for the quarter.
For more information or to listen to the call via webcast, please visit:
April 19, 2019 – Toronto, ON –
GREENBROOK TMS INC. TO PRESENT AT BLOOM BURTON CO. HEALTHCARE CONFERENCE
April 9, 2019 – Toronto, ON –
GREENBROOK TMS ANNOUNCES DATES FOR ITS FIRST QUARTER 2019 FINANCIAL RESULTS
April 2, 2019 – Toronto, ON –
GREENBROOK TMS SELECTED BY KAISER PERMANENTE AS PROVIDER OF TMS THERAPY SERVICES IN THE MID-ATLANTIC STATES
March 27, 2019 – Toronto, ON –
GREENBROOK TMS REPORTS FOURTH QUARTER AND YEAR END 2018 FINANCIAL RESULTS
February 26, 2019 – Toronto, ON –
GREENBROOK TMS ANNOUNCES DATES FOR ITS FOURTH QUARTER AND YEAR END 2018 FINANCIAL RESULTS